Acrivon Therapeutics (ACRV) Stock

Acrivon Therapeutics (ACRV) is a small-cap, clinical-stage biotechnology company focused on developing therapies in the anti‑infective and dermatology area. With a market capitalisation of about $64.17 million, the company is primarily valuation-driven by clinical progress, partnerships and regulatory milestones rather than steady revenues. Investors should expect binary events — clinical readouts, regulatory interactions or licensing deals — that can materially move the share price. Typical considerations include limited cash runway at smaller market caps, potential dilution from future financings, and long development timelines intrinsic to biotech. Due diligence should focus on the company’s pipeline, trial design and timelines, management experience, and cash position. This summary is general educational information and not personalised investment advice; biotech stocks can be volatile and investors may wish to consider how such high‑risk, high‑reward exposures fit with their broader portfolio and risk tolerance.